



STEATOHEPATITIS

RMA ID Number	Reference List for RMA324-3 as at August 2022
---------------	---

106128	Abarca JC, Huerta L, Fierro NA (2020). Antiretroviral therapies for human immunodeficiency virus and liver disease: challenges and opportunities. <i>Ann Hepatol</i> , 19(2): 121-2.
106129	Adams LA, Roberts SK, Strasser SI, et al (2020). Nonalcoholic fatty liver disease burden: Australia, 2019-2030. <i>J Gastroenterol Hepatol</i> , 35(9): 1628-35.
106130	Ahadi M, Molooghi K, Masoudifar N, et al (2021). A review of non-alcoholic fatty liver disease in non-obese and lean individuals. <i>J Gastroenterol Hepatol</i> , 36(6): 1497-507.
106131	Ajmera VH, Terrault NA, Harrison SA (2017). Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. <i>Hepatology</i> , 65(6): 2090-9.
106133	Ajmera VH, Terrault NA, VanWagner LB, et al (2019). Longer lactation duration is associated with decreased prevalence of non-alcoholic fatty liver disease in women. <i>J Hepatol</i> , 70(1): 126-32.
29739	Angelico F, Del Ben M, Conti R, et al (2003). Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. <i>J Gastroenterol Hepatol</i> , 18(5): 588-94.
36416	Angulo P (2002). Nonalcoholic fatty liver disease. <i>N Engl J Med</i> , 346(16): 1121-31.
36234	Angulo P, Keach JC, Batts KP, et al (1999). Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 30(6): 1356-62.
68473	Assy N, Nasser G, Kamayse I, et al (2008). Soft drink consumption linked with fatty liver in the absence of traditional risk factors. <i>Can J Gastroenterol</i> , 22(10): 811-6.
106135	Athyros VG, Polyzos SA, Kountouras J, et al (2020). Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. <i>Curr Vasc Pharmacol</i> , 18(2): 172-81.
106136	Australian Medicines Handbook (online) (2020). Tamoxifen. Retrieved 11 November 2020, from https://amhonline.amh.net.au/chapters/immunomodulators-antineoplastics/hormonal-antineoplastic-drugs/selective-estrogen-receptor-modulators/tamoxifen
106138	Azzaroli F, Mazzella G, Marchesini G, et al (2020). Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Rev Gastroenterol Hepatol</i> , 14(2): 127-35.

67234	Babu M, Paul N (2012). [Comment] Smoking and NASH: a hidden message from the GREACE trial. <i>J Hepatol</i> , 56: 300-1; author reply: 301-2. Comment on ID: 67233.
69372	Bacon B (2013). Genetic, metabolic and infiltrative diseases affecting the liver: introduction. Chapter 309, Retrieved 24 May 2013, from www.accessmedicine.com
106139	Barchetta I, Cimini FA, Cavallo MG (2017). Vitamin D supplementation and non-alcoholic fatty liver disease: present and future. <i>Nutrients</i> , 9(9): 1015.
106140	Barchetta I, Cimini FA, Cavallo MG (2020). Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update. <i>Nutrients</i> , 12(11): 3302.
106141	Barros BS, Santos DC, Pizarro MH, et al (2017). Type 1 diabetes and non-alcoholic fatty liver disease: when should we be concerned? A nationwide study in Brazil. <i>Nutrients</i> , 9(8): 878.
36797	Bellantani S, Saccoccio G, Masutti F, et al (2000). Prevalence of and risk factors for hepatic steatosis in Northern Italy. <i>Ann Intern med</i> , 132: 112-7.
106142	Bond A, Huijbers A, Pironi L, et al (2019). Review article: diagnosis and management of intestinal failure-associated liver disease in adults. <i>Aliment Pharmacol Ther</i> , 50(6): 640-53.
106143	Brar G, Tsukamoto H (2019). Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. <i>J Gastroenterol</i> , 54(3): 218-25.
106144	Bril F (2020). Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change. <i>Hepatobiliary Surg Nutr</i> , 9(4): 493-6.
106101	Brouquet A, Benoist S, Julie C, et al (2009). Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. <i>Surgery</i> , 145(4): 362-71. [Abstract]
35968	Bruno S, Maisonneuve P, Castellana P, et al (2005). Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. <i>BMJ</i> , 330(7497): 932-395.
67241	Caballeria L, Pera G, Auladell MA, et al (2010). Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. <i>Eur J Gastroenterol Hepatol</i> , 22(1): 24-32.
106145	Cai C, Song X, Chen Y, et al (2020). Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Hepatol Int</i> , 14(1): 115-26.
106099	Cai Z, Yang J, Shu X, et al (2014). Chemotherapy-associated hepatotoxicity in colorectal cancer. <i>J BUON</i> , 19(2): 350-6.
36795	Caldwell SH, Oelsner DH, Iezzoni JC, et al (1999). Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. <i>Hepatology</i> , 29(3): 664-9.
106146	Cano R, Perez JL, Davila LA, et al (2021). Role of endocrine-disrupting chemicals in the pathogenesis of non-alcoholic fatty liver disease: a comprehensive review. <i>Int J Mol Sci</i> , 22(9): 4807.
36792	Carvalho FM, Silvany-Neto AM, Cotrim HP, et al (2001). Epidemiological studies support an occupational etiology for nonalcoholic steatohepatitis among petrochemical workers from Bahia, Brazil. <i>J Hepatol</i> , 34(Suppl 1): S199.
35969	Castera L, Chouteau P, Hezode C, et al (2005). Hepatitis C virus-induced hepatocellular steatosis. <i>Am J Gastroenterol</i> , 100(3): 711-5.

106096	Cataldi M, Citro V, Resnati C, et al (2021). New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: much more than antioxidants. <i>Adv Ther</i> , 38(5): 2094-113.
106098	Cataldi M, Manco F, Tarantino G (2021). Steatosis, steatohepatitis and cancer immunotherapy: an intricate story. <i>Int J Mol Sci</i> , 22(23): 12947.
106147	Cazzo E, Pareja JC, Chaim EA (2017). Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. <i>Sao Paulo Med J</i> , 135(3): 277-95.
106148	Chaim FD, Pascoal LB, Chaim FH, et al (2020). Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. <i>Sci Rep</i> , 10(1): 8496.
67249	Chalasani N, Younossi Z, Lavine JE, et al (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 142(7): 1592-609.
67235	Chavez-Tapia NC, Lizardi-Cervera J, Perez-Bautista O, et al (2006). Smoking is not associated with nonalcoholic fatty liver disease. <i>World J Gastroenterol</i> , 12(32): 5196-200.
68183	Chavez-Tapia NC, Mendez-Sanchez N, Uribe M, et al (2005). [Comment] The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. <i>Ann Intern Med</i> , 144(5): 379-80; author reply: 380. Comment on ID: 68181.
67230	Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al (2010). Bariatric surgery for non-alcoholic steatohepatitis in obese patients. <i>Cochrane Database Syst Rev</i> , 2010(1): CD007340.
67245	Chen CH, Huang MH, Yang JC, et al (2006). Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. <i>J Clin Gastroenterol</i> , 40(8): 745-52.
106150	Chen H, Wang J, Li Z, et al (2019). Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis. <i>Int J Environ Res Public Health</i> , 16(12): 2192.
106151	Chen W, Li Y, Guo L, et al (2022). An umbrella review of systematic reviews and meta-analyses of observational investigations of obstructive sleep apnea and health outcomes. <i>Sleep Breath</i> , 26(1): 167-88.
106152	Chhimwal J, Patial V, Padwad Y (2021). Beverages and Non-alcoholic fatty liver disease (NAFLD): Think before you drink. <i>Clin Nutr</i> , 40(5): 2508-19.
36299	Chitturi S, Farrell GC (2001). Etiopathogenesis of nonalcoholic steatohepatitis. <i>Semin Liver Dis</i> , 21(1): 27-41.
103309	Chopra S, Lai M (2021). Management of nonalcoholic fatty liver disease in adults. Retrieved 9 September 2021, from https://www.uptodate.com/contents/management-of-nonalcoholic-fatty-liver-disease-in-adults
100954	Choudhary NS, Saigal S, Saraf N, et al (2019). [Comment] Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis. <i>Liver Transpl</i> , 25(6): 967-8. Comment on ID: 100946.
35973	Choudhury J, Sanyal AJ (2004). Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. <i>Clin Liver Dis</i> , 8(3): 575-94.

106154	Cimini FA, Barchetta I, Carotti S, et al (2017). Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. <i>World J Gastroenterol</i> , 23(19): 3407-17.
36297	Clark JM, Brancati FL, Diehl AM (2002). Nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 122: 1649-57.
29737	Clark JM, Diehl Am (2003). Nonalcoholic fatty liver disease. An underrecognized cause of cryptogenic cirrhosis. <i>JAMA</i> , 289(22): 3000-4.
67219	Colak Y, Tuncer I, Senates E, et al (2012). Nonalcoholic fatty liver disease: a nutritional approach. <i>Metab Syndr Relat Disord</i> , 10(3): 161-6.
35974	Contos MJ, Choudhury J, Mills AS, et al (2004). The histologic spectrum of nonalcoholic fatty liver disease. <i>Clin Liver Dis</i> , 8: 481-500.
36798	Cooper L, Palmer M, Oien K (2003). Cirrhosis with steatohepatitis following longterm stilboestrol treatment. <i>J Clin Pathol</i> , 56(8): 639.
106155	Coronel-Castillo CE, Qi X, Contreras-Carmona J, et al (2019). Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease. <i>Expert Rev Gastroenterol Hepatol</i> , 13(6): 531-40.
36298	Cotrim HP, Andrade ZA, Parana R, et al (1999). Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. <i>Liver</i> , 19(4): 299-304.
36320	Cotrim HP, Carvalho FM, de Freitas LA, et al (2001). Nonalcoholic steatohepatitis (NASH) and occupational exposure: a case-control study among petrochemical workers. <i>J Hepatol</i> , 34(Suppl 1): 229-30. [Abstract]
35975	Cotrim HP, De Freitas LA, Freitas C, et al (2004). Clinical and histopathological features of NASH in workers exposed to chemicals with or without associated metabolic conditions. <i>Liver Int</i> , 24(2): 131-5.
106156	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al (2010). Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. <i>Age Ageing</i> , 39(4): 412-23.
36035	Cua IH, George J (2005). Non-alcoholic fatty liver disease. <i>Hosp Med</i> , 66(2): 106-11.
67251	Cusi K (2009). Nonalcoholic fatty liver disease in type 2 diabetes mellitus. <i>Curr Opin Endocrinol Diabetes Obes</i> , 16(2): 141-9.
106157	Dallio M, Diano N, Masarone M, et al (2019). Chemical effect of bisphenol A on non-alcoholic fatty liver disease. <i>Int J Environ Res Public Health</i> , 16(17): 3134.
106087	Dash A, Figler RA, Sanyal AJ, et al (2017). Drug-induced steatohepatitis. <i>Expert Opin Drug Metab Toxicol</i> , 13(2): 193-204.
67242	Dassanayake AS, Kasturiratne A, Rajindrajith S, et al (2009). Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. <i>J Gastroenterol Hepatol</i> , 24(7): 1284-8.
36235	Day CP (2002). Pathogenesis of steatohepatitis. <i>Best Pract Res Clin Gastroenterol</i> , 16(5): 663-78.
106158	De Fre CH, De Fre MA, Kwanten WJ, et al (2019). Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity? <i>Obes Rev</i> , 20(2): 353-63.
106159	Deierlein AL, Rock S, Park S (2017). Persistent endocrine-disrupting chemicals and fatty liver disease. <i>Curr Environ Health Rep</i> , 4(4): 439-49.
106125	Di Pasqua LG, Cagna M, Berardo C, et al (2022). Detailed molecular mechanisms involved in drug-induced non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: an update. <i>Biomedicines</i> , 10(1): 194.

35967	Diehl AM (2005). Hepatic complications of obesity. <i>Gastroenterol Clin North Am</i> , 34(1): 45-61.
36300	Dixon JB, Prithi S, Bhathal PS, et al (2001). Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. <i>Gastroenterology</i> , 212: 91-100.
106160	Dooghaie Moghadam A, Eslami P, Razavi-Khorasani N, et al (2020). Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. <i>Caspian J Intern Med</i> , 11(4): 346-54.
36319	Dossing M, Ranek L (1984). Isolated liver damage in chemical workers. <i>Br J Ind Med</i> , 41(1): 142-4.
106161	Ekstedt M, Franzen LE, Holmqvist M, et al (2009). Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. <i>Scand J Gastroenterol</i> , 44(3): 366-74.
106162	El Sherif O, Dhaliwal A, Newsome PN, et al (2020). Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. <i>Expert Rev Gastroenterol Hepatol</i> , 14(3): 197-205.
106163	Emhmed Ali S, Nguyen MH (2021). Sarcopenic obesity in non-alcoholic fatty liver disease-the union of two culprits. <i>Life (Basel)</i> , 11(2): 119.
106164	Esquivel CM, Garcia M, Armando L, et al (2018). Laparoscopic sleeve gastrectomy resolves NAFLD: another formal indication for bariatric surgery? <i>Obes Surg</i> , 28(12): 4022-33.
68478	European Association for the Study of the Liver (2012). EASL clinical practical guidelines: management of alcoholic liver disease. <i>J Hepatol</i> , 57(2): 399-420.
36302	Farrell GC (2002). Drugs and steatohepatitis. <i>Semin Liver Dis</i> , 22(2): 185-94.
106166	Federico A, Rosato V, Masarone M, et al (2021). The role of fructose in non-alcoholic steatohepatitis: old relationship and new insights. <i>Nutrients</i> , 13(4): 1314.
106167	Foulds CE, Trevino LS, York B, et al (2017). Endocrine-disrupting chemicals and fatty liver disease. <i>Nat Rev Endocrinol</i> , 13(8): 445-57.
106168	Fousekis FS, Mitselos IV, Christodoulou DK (2021). New insights into intestinal failure-associated liver disease in adults: A comprehensive review of the literature. <i>Saudi J Gastroenterol</i> , 27(1): 3-12.
68471	Friedman SL (2013). Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis. Retrieved 3 July 2013, from http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-alcoholic-fatty-liver-disease-and-alcoholic-cirrhosis
103193	Friedman SL (2020). Management and prognosis of alcoholic hepatitis. Retrieved 9 September 2021, from https://www.uptodate.com/contents/management-and-prognosis-of-alcoholic-hepatitis
103194	Friedman SL (2021). Clinical manifestations and diagnosis of alcohol-associated fatty liver disease and cirrhosis. Retrieved 9 September 2021, from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-alcohol-associated-fatty-liver-disease-and-cirrhosis
106169	Gabe SM (2013). Lipids and liver dysfunction in patients receiving parenteral nutrition. <i>Curr Opin Clin Nutr Metab Care</i> , 16(2): 150-5.
100946	Galvin Z, Rajakumar R, Chen E, et al (2019). Predictors of de novo nonalcoholic fatty liver disease after liver transplantation and associated fibrosis. <i>Liver Transpl</i> , 25(1): 56-67.

67252	Gao B, Bataller R (2011). Alcoholic liver disease: pathogenesis and new therapeutic targets. <i>Gastroenterology</i> , 141(5): 1572-85.
106170	Garcia-Roman R, Frances R (2020). Acetaminophen-induced liver damage in hepatic steatosis. <i>Clin Pharmacol Ther</i> , 107(5): 1068-81.
67258	Gastaldelli A (2010). [Comment] Fatty liver disease: the hepatic manifestation of metabolic syndrome. <i>Hypertens Res</i> , 33(6): 546-7. Comment on ID: 67257.
106171	George ES, Forsyth A, Itsiopoulos C, et al (2018). Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults. <i>Adv Nutr</i> , 9(1): 30-40.
106089	Gervasoni C, Cattaneo D, Filice C, et al (2019). Drug-induced liver steatosis in patients with HIV infection. <i>Pharmacol Res</i> , 145: 104267.
106172	Golabi P, Locklear CT, Austin P, et al (2016). Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. <i>World J Gastroenterol</i> , 22(27): 6318-27.
106173	Gong S, Song J, Wang L, et al (2016). Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Eur J Gastroenterol Hepatol</i> , 28(2): 132-8.
106174	Guo XF, Wang C, Yang T, et al (2020). Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. <i>Food Funct</i> , 11(9): 7389-99.
102896	Hagstrom H, Nasr P, Ekstedt M, et al (2017). Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scand J Gastroenterol</i> , 52(2): 159-65.
67236	Hamabe A, Uto H, Imamura Y, et al (2011). Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. <i>J Gastroenterol</i> , 46(6): 769-78.
68181	Hamaguchi M, Kojima T, Takeda N, et al (2005). The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. <i>Ann Intern Med</i> , 143(10): 722-8.
106091	Han J, Zhang J, Zhang C (2021). Irinotecan-induced steatohepatitis: current insights. <i>Front Oncol</i> , 11: 754891.
106175	Harris RH, Sasson G, Mehler PS (2013). Elevation of liver function tests in severe anorexia nervosa. <i>Int J Eat Disord</i> , 46(4): 369-74.
36236	Harrison SA, Kadakia S, Lang KA, et al (2002). Nonalcoholic steatohepatitis: what we know in the new millennium. <i>Am J Gastroenterol</i> , 97(11): 2714-24.
29736	Harrison SA, Torgerson S, Hayashi PH (2003). [Comment] The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. <i>Am J Gastroenterol</i> , 98(9): 2042-7.
69373	Harrison's Online (2013). Alcoholic liver disease. Chapter 307, Retrieved 30 May 2013, from www.accessmedicine.com
106176	Hassani Zadeh S, Mansoori A, Hosseinzadeh M (2021). Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>J Gastroenterol Hepatol</i> , 36(6): 1470-8.
106177	Hayat U, Siddiqui AA, Okut H, et al (2021). The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies. <i>Ann Hepatol</i> , 20: 100254.
106178	He K, Li Y, Guo X, et al (2020). Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Br J Nutr</i> , 124(1): 1-13.

67255	He S, Bao W, Shao M, et al (2011). Risk factors for non-alcoholic fatty liver disease in a Chinese population. <i>Acta Gastroenterol Belg</i> , 74(4): 503-8.
106179	Hocking MP, Duerson MC, O'Leary JP, et al (1983). Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. <i>N Engl J Med</i> , 308(17): 995-9.
106180	Hojland Ipsen D, Tveden-Nyborg P, Lykkesfeldt J (2016). Normal weight dyslipidemia: Is it all about the liver? <i>Obesity (Silver Spring)</i> , 24(3): 556-67.
106181	Hu XY, Li Y, Li LQ, et al (2018). Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey. <i>BMJ Open</i> , 8(4): e019974.
106182	Hydes T, Alam U, Cuthbertson DJ (2021). The impact of macronutrient intake on non-alcoholic fatty liver disease (NAFLD): too much fat, too much carbohydrate, or just too many calories? <i>Front Nutr</i> , 8: 640557.
67226	Ibdah JA (2006). Acute fatty liver of pregnancy: an update on pathogenesis and clinical implications. <i>World J Gastroenterol</i> , 12(46): 7397-404.
106183	Isaza SC, Del Pozo-Maroto E, Domiguez-Alcon L, et al (2020). Hypoxia and non-alcoholic fatty liver disease. <i>Front Med (Lausanne)</i> , 7: 578001.
106184	Ito Y, Kenmochi T, Shibutani S, et al (2014). Evaluation of predictive factors in patients with nonalcoholic fatty liver disease after pancreaticoduodenectomy. <i>Am Surg</i> , 80(5): 500-4.
36417	Jansen PL (2004). Nonalcoholic steatohepatitis. <i>Neth J Med</i> , 62(7): 217-24.
106185	Jaruvongvanich V, Ahuja W, Wijarnpreecha K, et al (2017). Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Eur J Gastroenterol Hepatol</i> , 29(6): 694-7.
106186	Jaruvongvanich V, Ahuja W, Wirunsawanya K, et al (2017). Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>Eur J Gastroenterol Hepatol</i> , 29(9): 1031-5.
106187	Jarvis H, Craig D, Barker R, et al (2020). Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. <i>PLoS Med</i> , 17(4): e1003100.
67231	Javor ED, Ghany MG, Cochran EK, et al (2005). Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. <i>Hepatology</i> , 41(4): 753-60.
67240	Ji HF, Shen L (2010). [Comment] Uric acid potentially links fatty liver and high blood pressure. <i>Hepatology</i> , 52(4): 1518-9; author reply: 1519. Comment on ID: 67238.
106188	Jia G, Shu XO, Liu Y, et al (2019). Association of adult weight gain with major health outcomes among middle-aged Chinese persons with low body weight in early adulthood. <i>JAMA Netw Open</i> , 2(12): e1917371.
67243	Jiang BQ, Zhong PH, Cheng XB, et al (2007). Investigation of health and nutrition status of middle-aged and old residents in the urban district of Chongqing. <i>Asia Pac J Clin Nutr</i> , 16(Suppl 1): 17-21.
106189	Jin S, Jiang S, Hu A (2018). Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>Sleep Breath</i> , 22(3): 841-51.

106190	Kapoor N, Audsley J, Rupali P, et al (2019). A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. <i>AIDS</i> , 33(7): 1105-15.
67223	Kato H, Isaji S, Azumi Y, et al (2010). Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system. <i>J Hepatobiliary Pancreat Sci</i> , 17(3): 296-304.
106191	Katsiki N, Mikhailidis DP, Mantzoros CS (2016). Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism</i> , 65(8): 1109-23.
67228	Kechagias S, Zanjani S, Gjellan S, et al (2011). Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. <i>Ann Med</i> , 43(7): 545-54.
106192	Khalaf RT, Sokol RJ (2020). New insights into intestinal failure-associated liver disease in children. <i>Hepatology</i> , 71(4): 1486-98.
106193	Kim D, Kim WR (2017). Nonobese fatty liver disease. <i>Clin Gastroenterol Hepatol</i> , 15(4): 474-85.
106194	Kim G, Lee SE, Lee YB, et al (2018). Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a 7-year longitudinal study. <i>Hepatology</i> , 68(5): 1755-68.
106195	Kim JA, Choi KM (2019). Sarcopenia and fatty liver disease. <i>Hepatol Int</i> , 13(6): 674-87.
106196	Kim NH, Kim JH, Kim YJ, et al (2014). Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. <i>Liver Int</i> , 34(4): 604-11.
106083	Knebel B, Muller-Wieland D, Kotzka J (2020). Lipodystrophies-disorders of the fatty tissue. <i>Int J Mol Sci</i> , 21(22): 8778.
106093	Kolaric TO, Nincevic V, Kuna L, et al (2021). Drug-induced fatty liver disease: pathogenesis and treatment. <i>J Clin Transl Hepatol</i> , 9(5): 731-7.
106197	Koo BK, Kim D, Joo SK, et al (2017). Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. <i>J Hepatol</i> , 66(1): 123-31.
67215	Kopec KL, Burns D (2011). Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. <i>Nutr Clin Pract</i> , 26(5): 565-76.
106198	Korbonits M, Blaine D, Elia M, et al (2007). Metabolic and hormonal changes during the refeeding period of prolonged fasting. <i>Eur J Endocrinol</i> , 157(2): 157-66.
106199	Kwon I, Jun DW, Moon JH (2019). Effects of moderate alcohol drinking in patients with nonalcoholic fatty liver disease. <i>Gut Liver</i> , 13(3): 308-14.
67259	Kwon YM, Oh SW, Hwang SS, et al (2012). Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. <i>Am J Gastroenterol</i> , 107(12): 1852-8.
36799	Langman G, Hall PM, Todd G (2001). Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. <i>J Gastroenterol Hepatol</i> , 16(12): 1395-401.
106200	Lao TT (2020). Implications of abnormal liver function in pregnancy and non-alcoholic fatty liver disease. <i>Best Pract Res Clin Obstet Gynaecol</i> , 68: 2-11.
67217	Larrain S, Rinella ME (2012). A myriad of pathways to NASH. <i>Clin Liver Dis</i> , 16(3): 525-48.

106201	Lavrentaki A, Thomas T, Subramanian A, et al (2019). Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: A population-based cohort study, systematic review and meta-analysis. <i>J Diabetes Complications</i> , 33(10): 107401.
103040	Lazarevic N, Smurthwaite K, Trevenar S, et al (2021). PFAS Health Study Component Three: Cross-Sectional Survey of Self-Reported Physical and Mental Health Outcomes and Associations with Blood Serum PFAS. Canberra (AU): The Australian National University.
103549	Lee MJ, Kim EH, Bae SJ, et al (2019). Age-related decrease in skeletal muscle mass is an independent risk factor for incident nonalcoholic fatty liver disease: a 10-year retrospective cohort study. <i>Gut Liver</i> , 13(1): 67-76.
106212	Lee SW, Lee TY, Yang SS, et al (2018). Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. <i>Hepatobiliary Pac</i> , 17(1): 45-58.
106213	Lee YH, Jung KS, Kim SU, et al (2015). Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). <i>J Hepatol</i> , 63(2): 486-93.
106214	Li XX, Cheng YC, Zhai SD, et al (2021). Risk of liver injury associated with intravenous lipid emulsions: a prescription sequence symmetry analysis. <i>Front Pharmacol</i> , 12: 589091.
106215	Lonardo A, Mantovani A, Lugari S, et al (2019). NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. <i>Int J Mol Sci</i> , 20(11): 2841.
106216	Lonardo A, Nascimbeni F, Mantovani A, et al (2018). Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? <i>J Hepatol</i> , 68(2): 335-52.
67237	Lopez-Suarez A, Guerrero JM, Elvira-Gonzalez J, et al (2011). Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. <i>Eur J Gastroenterol Hepatol</i> , 23(11): 1011-7.
67900	Loria P, Carulli L, Bertolotti M, et al (2009). Endocrine and liver interaction: the role of endocrine pathways in NASH. <i>Nat Rev Gastroenterol Hepatol</i> , 6(4): 236-47.
106217	Losurdo G, Castellaneta A, Rendina M, et al (2018). Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. <i>Aliment Pharmacol Ther</i> , 47(6): 704-14.
106218	Lu FB, Hu ED, Xu LM, et al (2018). The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. <i>Expert Rev Gastroenterol Hepatol</i> , 12(5): 491-502.
106219	Lu ZY, Shao Z, Li YL, et al (2016). Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study. <i>World J Gastroenterol</i> , 22(13): 3663-9.
106220	Luu C, Thapa R, Rose T, et al (2018). Identification of nonalcoholic fatty liver disease following pancreatotomy for noninvasive intraductal papillary mucinous neoplasm. <i>Int J Surg</i> , 58: 46-9.
106221	Macias J, Pineda JA, Real LM (2017). Non-alcoholic fatty liver disease in HIV infection. <i>AIDS Rev</i> , 19(1): 35-46.
106222	Mackay TM, Genc CG, Takkenberg RB, et al (2018). New onset non-alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors. <i>J Surg Oncol</i> , 117(7): 1548-55.

106223	Mahady SE, George J (2016). Exercise and diet in the management of nonalcoholic fatty liver disease. <i>Metabolism</i> , 65(8): 1172-82.
106224	Mahli A, Hellerbrand C (2016). Alcohol and obesity: a dangerous association for fatty liver disease. <i>Dig Dis</i> , 34(Suppl 1): 32-9.
106225	Mahmoodi M, Hosseini R, Kazemi A, et al (2020). Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials. <i>Phytother Res</i> , 34(7): 1587-98.
94100	Mantovani A, Byrne CD, Bonora E, et al (2018). Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. <i>Diabetes Care</i> , 41(2): 372-82.
106316	Mantovani A, Turino T, Altomari A, et al (2019). Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism</i> , 96: 56-65.
106226	Marchesini G, Petta S, Dalle Grave R (2016). Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 63(6): 2032-43.
68185	Marchesini G, Suppini A, Forlani G (2005). [Comment] NAFLD treatment: cognitive-behavioral therapy has entered the arena. <i>J Hepatol</i> , 43(6): 926-8. Comment on ID: 68184.
106227	Marubbio AT Jr, Buchwald H, Schwartz MZ, et al (1976). Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. <i>Am J Clin Pathol</i> , 66(4): 684-91.
30006	Mascitelli L, Pezzetta F (2003). Diagnosis of nonalcoholic fatty liver disease. <i>JAMA</i> , 290(12): 1577-8.
106228	Mathews SE, Kumar RB, Shukla AP (2018). Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. <i>Curr Opin Endocrinol Diabetes Obes</i> , 25(5): 315-20.
106229	Mato JM, Alonso C, Noureddin M, et al (2019). Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. <i>World J Gastroenterol</i> , 25(24): 3009-20.
35972	McClain CJ, Mokshagundam SP, Barve SS, et al (2004). Mechanisms of non-alcoholic steatohepatitis. <i>Alcohol</i> , 34: 67-79.
106230	McGhee-Jez AE, Chervoneva I, Yi M, et al (2021). Nonalcoholic fatty liver disease after pancreaticoduodenectomy for a cancer diagnosis. <i>J Pancreat Cancer</i> , 7(1): 23-30.
100947	McNeice A, Scott R, Rafferty GP, et al (2019). The hepatobiliary complications of malnutrition and nutritional support in adults. <i>Ir J Med Sci</i> , 188(1): 109-17.
36031	Mendez-Sanchez N, Almeda-Valdes PA, Uribe M (2005). Alcoholic liver disease. An update. <i>Ann Hepatol</i> , 4(1): 32-42.
106231	Mendez-Sanchez N, Cerda-Reyes E, Higuera-de-la-Tijera F, et al (2020). Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. <i>F1000Res</i> , 9: 56.
106232	Merli M, Lattanzi B, Aprile F (2019). Sarcopenic obesity in fatty liver. <i>Curr Opin Clin Nutr Metab Care</i> , 22(3): 185-90.
106233	Mesarwi OA, Loomba R, Malhotra A (2019). Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease. <i>Am J Respir Crit Care Med</i> , 199(7): 830-41.
106094	Meunier L, Larrey D (2020). Chemotherapy-associated steatohepatitis. <i>Ann Hepatol</i> , 19(6): 597-601.
106085	Miele L, Liguori A, Marrone G, et al (2017). Fatty liver and drugs: the two sides of the same coin. <i>Eur Rev Med Pharmacol Sci</i> , 21(1 Suppl): 86-94.

106234	Mikolasevic I, Filipec-Kanizaj T, Mijic M, et al (2018). Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? <i>World J Gastroenterol</i> , 24(14): 1491-506.
106235	Morrison AE, Zaccardi F, Khunti K, et al (2019). Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. <i>Liver Int</i> , 39(3): 557-67.
67218	Mouzaki M, Allard JP (2012). The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. <i>J Clin Gastroenterol</i> , 46(6): 457-67.
106236	Mundi MS, Klek S, Martindale RG (2020). Use of lipids in adult patients requiring parenteral nutrition in the home setting. <i>JPEN J Parenter Enteral Nutr</i> , 44(Suppl 1): S39-44.
106237	Musso G, Cassader M, Olivetti C, et al (2013). Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. <i>Obes Rev</i> , 14(5): 417-31.
106238	Nakagawa N, Murakami Y, Uemura K, et al (2014). Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency. <i>J Surg Oncol</i> , 110(6): 720-6.
88312	Narayanan V, Gaudiani JL, Harris RH, et al (2010). Liver function test abnormalities in anorexia nervosa--cause or effect. <i>Int J Eat Disord</i> , 43(4): 378-81.
106104	National Institute of Diabetes and Digestive and Kidney Diseases (2016). Toremfene. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548338/
106106	National Institute of Diabetes and Digestive and Kidney Diseases (2019). Lomitapide. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548458/
106110	National Institute of Diabetes and Digestive and Kidney Diseases (2019). Tetracyclines. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548040/
106111	National Institute of Diabetes and Digestive and Kidney Diseases (2020). Tamoxifen. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548902/
106112	National Institute of Diabetes and Digestive and Kidney Diseases (2017). Angiotensin II receptor antagonists. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548642/
106107	National Institute of Diabetes, Digestive and Kidney Diseases (2018). Irinotecan. Retrieved 30 March 2022, from https://www.ncbi.nlm.nih.gov/books/NBK548037/
100949	Neuberg M, Triantafyllidis I, Lefevre M, et al (2021). Does chemotherapy-induced liver injury impair postoperative outcomes after laparoscopic liver resection for colorectal metastases? <i>J Gastrointest Surg</i> , 25(5): 1203-11.
36579	Neuschwander-Tetri BA, Caldwell SH (2003). Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. <i>Hepatology</i> , 37(5): 1202-19.
106239	Nickel F, Tapking C, Benner L, et al (2018). Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up : BariScan Study. <i>Obes Surg</i> , 28(5): 1342-50.
106240	Ning L, Liu R, Lou X, et al (2019). Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. <i>Eur J Gastroenterol Hepatol</i> , 31(7): 735-42.

106241	Nishioka H, Yoshizaki A, Imai Y, et al (2019). Starvation-induced liver enzyme elevation after initiation of feeding. <i>Intern Med</i> , 58(5): 749-53.
67253	No authors listed (2011). Metabolic disorders associated with obstructive sleep apnea in adults. <i>Adv Cardiol</i> , 46: 67-138.
67221	Nomura K, Yamanouchi T (2012). The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. <i>J Nutr Biochem</i> , 23(3): 203-8.
106242	Nseir W, Mahamid M (2013). Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review. <i>Curr Atheroscler Rep</i> , 15(3): 305.
100950	Okabe H, Yamashita YI, Inoue R, et al (2020). Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy. <i>Surg Today</i> , 50(2): 193-9.
106243	Okamura T, Hashimoto Y, Hamaguchi M, et al (2021). Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study. <i>BMC Gastroenterol</i> , 21(1): 223.
29735	Ong JP, Younossi ZM (2003). [Comment] Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history? <i>Am J Gastroenterol</i> , 98(9): 1915-7.
68470	O'Shea RS, Dasarathy S, McCullough AJ, et al (2010). Alcoholic liver disease. <i>Hepatology</i> , 51(1): 307-28.
67260	Pagadala MR, McCullough AJ (2012). [Comment] Non-alcoholic fatty liver disease and obesity: not all about body mass index. <i>Am J Gastroenterol</i> , 107: 1859-61. Comment on ID: 67259.
36796	Pagano G, Pacini G, Musso G, et al (2002). Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. <i>Hepatology</i> , 35: 367-72.
106244	Pan X, Han Y, Zou T, et al (2018). Sarcopenia contributes to the progression of nonalcoholic fatty liver disease-related fibrosis: a meta-analysis. <i>Dig Dis</i> , 36(6): 427-36. [Abstract]
106245	Papagianni M, Tziomalos K (2018). Non-alcoholic fatty liver disease in patients with HIV infection. <i>AIDS Rev</i> , 20(3): 171-3.
67246	Park SH, Jeon WK, Kim SH, et al (2006). Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. <i>J Gastroenterol Hepatol</i> , 21(1 Pt 1): 138-43.
106114	Patel V, Sanyal AJ (2013). Drug-induced steatohepatitis. <i>Clin Liver Dis</i> , 17(4): 533-46.
106246	Patil DT, Yerian LM (2012). Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. <i>Liver Transpl</i> , 18(10): 1147-53.
106247	Petta S, Eslam M, Valenti L, et al (2017). Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver Int</i> , 37(9): 1389-96.
106248	Polyzos SA, Kountouras J, Mantzoros CS (2019). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Metabolism</i> , 92: 82-97.
36794	Poonawala A, Nair SP, Thuluvath PJ (2003). Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. <i>Hepatology</i> , 32: 689-92.
36059	Portincasa P, Grattagliano I, Palmieri VO, et al (2005). The emerging problem of nonalcoholic steatohepatitis (NASH). <i>Rom J Gastroenterol</i> , 14(1): 43-51.

68182	Powll EE, Jonsson JR, Clouston AD (2005). [Comment] Dangerous liaisons: the metabolic syndrome and nonalcoholic fatty liver disease. <i>Ann Intern Med</i> , 143(10): 753-4. Comment on ID: 68181.
106249	Praveen Raj P, Gomes RM, Kumar S, et al (2015). The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: "NASHOST" prospective observational trial. <i>Surg Obes Relat Dis</i> , 11(6): 1315-22.
106250	Price JC, Seaberg EC, Latanich R, et al (2014). Risk factors for fatty liver in the Multicenter AIDS Cohort Study. <i>Am J Gastroenterol</i> , 109(5): 695-704.
106251	PubChem (2022). Amineptine. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/Amineptine
106252	PubChem (2022). Bis(2-ethylhexyl) maleate. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/5365125
106253	PubChem (2022). Didanosine. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/135398739
106254	PubChem (2022). Dihydrodiethylstilbestrol. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/3606
106255	PubChem (2022). Fialuridine. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/50313
106256	PubChem (2022). Tianeptine. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/68870
106257	PubChem (2022). Troglitazone. Retrieved 31 March 2022, from https://pubchem.ncbi.nlm.nih.gov/compound/5591
106116	Rabinowich L, Shibolet O (2015). Drug induced steatohepatitis: an uncommon culprit of a common disease. <i>Biomed Res Int</i> , 2015: 168905.
67225	Raman M, Allard JP (2007). Parenteral nutrition related hepato-biliary disease in adults. <i>Appl Physiol Nutr Metab</i> , 32: 646-54.
106258	Ranjbar G, Mikhailidis DP, Sahebkar A (2019). Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! <i>Metabolism</i> , 101: 154001.
68476	Rector RS, Thyfault JP (2011). Does physical inactivity cause nonalcoholic fatty liver disease? <i>J Appl Physiol</i> (1985), 111(6): 1828-35.
67224	Rector RS, Thyfault JP, Wei Y, Ibdah JA (2008). Non-alcoholic fatty liver disease and the metabolic syndrome: an update. <i>World J Gastroenterol</i> , 14(2): 185-92.
106259	Requarth JA, Burchard KW, Colacchio TA, et al (1995). Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. <i>Arch Surg</i> , 130(3): 318-25.
106260	Risi R, Tuccinardi D, Mariani S, et al (2021). Liver disease in obesity and underweight: the two sides of the coin. A narrative review. <i>Eat Weight Disord</i> , 26(7): 2097-107.
106261	Rochling FA (2021). Intravenous lipid emulsions in the prevention and treatment of liver disease in intestinal failure. <i>Nutrients</i> , 13(3): 895.
100944	Rockstroh JK (2017). Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in HIV. <i>Curr HIV/AIDS Rep</i> , 14(2): 47-53.
106262	Roeb E, Weiskirchen R (2021). Fructose and non-alcoholic steatohepatitis. <i>Front Pharmacol</i> , 12: 634344.
106263	Rosen E, Bakshi N, Watters A, et al (2017). Hepatic complications of anorexia nervosa. <i>Dig Dis Sci</i> , 62(11): 2977-81.

106264	Saeed N, Glass L, Sharma P, et al (2019). Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis. <i>Transplantation</i> , 103(11): e345-54.
106265	Sakada M, Tanaka A, Ohta D, et al (2006). Severe steatosis resulted from anorexia nervosa leading to fatal hepatic failure. <i>J Gastroenterol</i> , 41(7): 714-5.
67239	Salamone F, Galvano F, Li Volti G (2010). [Comment] Treating fatty liver for the prevention of cardiovascular diseases. <i>Hepatology</i> , 52(3): 1174-5. Comment on ID: 67238.
67229	Sanada Y, Urahashi T, Wakiya T, et al (2011). Non-alcoholic steatohepatitis caused by malnutrition after pediatric liver transplantation. <i>Pediatr Int</i> , 53(6): 1077-81.
100951	Sarkar M, Grab J, Dodge JL, et al (2020). Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. <i>J Hepatol</i> , 73(3): 516-22.
35971	Sass DA, Chang P, Chopra KB (2005). Nonalcoholic fatty liver disease: a clinical review. <i>Dig Dis Sci</i> , 50(1): 171-80.
106124	Satapathy SK, Kuwajima V, Nadelson J, et al (2015). Drug-induced fatty liver disease: An overview of pathogenesis and management. <i>Ann Hepatol</i> , 14(6): 789-806.
67250	Scaglioni F, Ciccia S, Marino M, et al (2011). ASH and NASH. <i>Dig Dis</i> , 29(2): 202-10.
106122	Schumacher JD, Guo GL (2015). Mechanistic review of drug-induced steatohepatitis. <i>Toxicol Appl Pharmacol</i> , 289(1): 40-7.
106266	Sheka AC, Adeyi O, Thompson J, et al (2020). Nonalcoholic steatohepatitis: a review. <i>JAMA</i> , 323(12): 1175-83.
106267	Shen R, Ye ZC, Gao J, et al (2018). Climate change risk perception in global: Correlation with petroleum and liver disease: A meta-analysis. <i>Ecotoxicol Environ Saf</i> , 166: 453-61.
67227	Shen Z, Li Y, Yu C, et al (2010). A cohort study of the effect of alcohol consumption and obesity on serum liver enzyme levels. <i>Eur J Gastroenterol Hepatol</i> , 22(7): 820-5.
68472	Sheth SG, Chopra S (2013). Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. Retrieved 3 July 2013, from http://www.uptodate.com/contents/epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults
36301	Sheth SG, Gordon FD, Chopra S (1997). Nonalcoholic steatohepatitis. <i>Ann Intern Med</i> , 126(2): 137-45.
106268	Shetty A, Giron F, Divatia MK, et al (2021). Nonalcoholic fatty liver disease after liver transplant. <i>J Clin Transl Hepatol</i> , 9(3): 428-35.
106269	Singear AM, Stanciu C, Huiban L, et al (2021). Association between nonalcoholic fatty liver disease and endocrinopathies: clinical implications. <i>Can J Gastroenterol Hepatol</i> , 2021: 6678142.
54118	Singh D, Laya AS, Clarkston WK, et al (2009). Jejunoileal bypass: a surgery of the past and a review of its complications. <i>World J Gastroenterol</i> , 15(18): 2277-9.
106270	Slomko J, Zalewska M, Niemiro W, et al (2021). Evidence-based aerobic exercise training in metabolic-associated fatty liver disease: systematic review with meta-analysis. <i>J Clin Med</i> , 10(8): 1659.
67256	Smith BW, Adams LA (2011). Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. <i>Nat Rev Endocrinol</i> , 7: 456-65.

103039	Smurthwaite K, Lazarevic N, Braunig J, et al (2021). PFAS Health Study Component Two: Blood Serum Study of PFAS Exposure, Related Risk Factors and Biochemical Markers of Health. Canberra (AU): The Australian National University.
106271	Solbach HG, Franken FH (1969). The liver in chronic undernutrition. <i>Ger Med Mon</i> , 14(6): 271-5.
106272	Sookoian S, Pirola CJ (2013). Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. <i>Obes Surg</i> , 23(11): 1815-25.
106273	Sookoian S, Pirola CJ (2017). Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. <i>Aliment Pharmacol Ther</i> , 46(2): 85-95.
106274	Sookoian S, Pirola CJ (2018). Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. <i>Aliment Pharmacol Ther</i> , 47(1): 16-25.
67220	Souza MR, Diniz Mde F, Medeiros-Filho JE, et al (2012). Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. <i>Arq Gastroenterol</i> , 49(1): 89-96.
67238	Speliotes EK, Massaro JM, Hoffmann U, et al (2010). Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. <i>Hepatology</i> , 51(6): 1979-87.
106275	Squillace N, Soria A, Bozzi G, et al (2019). Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. <i>Expert Rev Gastroenterol Hepatol</i> , 13(7): 643-50.
29738	Stravitz RT, Sanyal AJ (2003). Drug-induced steatohepatitis. <i>Clin Liver Dis</i> , 7(2): 435-51.
68184	Suzuki A, Lindor K, St Saver J, et al (2005). Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. <i>J Hepatol</i> , 43(6): 1060-6.
106276	Tan CH, Al-Kalifah N, Ser KH, et al (2018). Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. <i>Surg Obes Relat Dis</i> , 14(10): 1600-6.
106277	Tanaka N, Horiuchi A, Yokoyama T, et al (2011). Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. <i>J Gastroenterol</i> , 46(6): 758-68.
106278	Taneja S, Roy A (2020). Nonalcoholic steatohepatitis recurrence after liver transplant. <i>Transl Gastrointest Hepatol</i> , 5: 24.
35966	Tanne F, Gagnadoux F, Chazouilleres O, et al (2005). Chronic Liver Injury During Obstructive Sleep Apnea. <i>Hepatology</i> , 41: 1290-6.
36237	Teli MR, James OF, Burt AD, et al (1995). The natural history of nonalcoholic fatty liver: a follow-up study. <i>Hepatology</i> , 22(6): 1714-9.
103195	Tendler DA (2020). Pathogenesis of nonalcoholic fatty liver disease. Retrieved 9 September 2021, from https://www.uptodate.com/contents/pathogenesis-of-nonalcoholic-fatty-liver-disease
106279	Tsai JH, Ferrell LD, Tan V, et al (2017). Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. <i>Mod Pathol</i> , 30(6): 834-42.
67257	Tsuneto A, Hida A, Sera N, et al (2010). Fatty liver incidence and predictive variables. <i>Hypertens Res</i> , 33(6): 638-43.

106280	Umbro I, Fabiani V, Fabiani M, et al (2020). Association between non-alcoholic fatty liver disease and obstructive sleep apnea. <i>World J Gastroenterol</i> , 26(20): 2669-81.
106281	Vancells Lujan P, Vinas Esmel E, Sacanella Meseguer E (2021). Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. <i>Nutrients</i> , 13(5): 1442.
106282	Verna EC (2017). Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. <i>Lancet Gastroenterol Hepatol</i> , 2(3): 211-23.
67216	Verna EC, Berk PD (2008). Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. <i>Semin Liver Dis</i> , 28(4): 407-26.
100821	Vinceti M, Filippini T, Wise LA (2018). Environmental selenium and human health: an update. <i>Curr Environ Health</i> , 5(4): 464-85.
106283	Vootla VR, Daniel M (2015). Abnormal liver function tests in an anorexia nervosa patient and an atypical manifestation of refeeding syndrome. <i>Case Rep Gastroenterol</i> , 9(2): 261-5.
106284	Vyberg M, Ravn V, Andersen B (1987). Pattern of progression in liver injury following jejunoileal bypass for morbid obesity. <i>Liver</i> , 7(5): 271-6.
106285	Walenbergh SM, Shiri-Sverdlov R (2015). Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. <i>Expert Rev Gastroenterol Hepatol</i> , 9(11): 1343-6.
106121	Wang Q, Huang A, Wang JB, et al (2021). Chronic drug-induced liver injury: updates and future challenges. <i>Front Pharmacol</i> , 12: 627133.
106286	Wang ST, Zheng J, Peng HW, et al (2020). Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. <i>BMC Gastroenterol</i> , 20(1): 66.
106287	Wang T, Yang W, Karakas S, et al (2018). NASH in nondiabetic endocrine disorders. <i>Metab Syndr Relat Disord</i> , 16(7): 315-20.
67254	Wang Y, Dong J, Liu HY, et al (2010). Biochemical characteristics and risk factors in non-alcoholic fatty liver. <i>Front Biosci (Elite Ed)</i> , 2(1): 105-10.
106288	Wanten GJ (2015). Parenteral lipids: safety aspects and toxicity. <i>World Rev Nutr Diet</i> , 112: 63-70.
106289	Wei F, Li J, Chen C, et al (2020). Higher serum uric acid level predicts non-alcoholic fatty liver disease: a 4-year prospective cohort study. <i>Front Endocrinol (Lausanne)</i> , 11: 179.
106118	White MA, Fong Y, Singh G (2016). Chemotherapy-associated hepatotoxicities. <i>Surg Clin North Am</i> , 96(2): 207-17.
106298	Wijarnpreecha K, Panjawan P, Lekuthai N, et al (2017). Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis. <i>Liver Int</i> , 37(6): 906-18.
106299	Wijarnpreecha K, Thongprayoon C, Panjawan P, et al (2016). Short sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>J Gastroenterol Hepatol</i> , 31(11): 1802-7.
106300	Wijarnpreecha K, Thongprayoon C, Panjawan P, et al (2017). Insomnia and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>J Postgrad Med</i> , 63(4): 226-31.
106301	Wijarnpreecha K, Thongprayoon C, Panjawan P, et al (2018). Helicobacter pylori and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. <i>J Clin Gastroenterol</i> , 52(5): 386-91.

67248	Williams CD, Stengel J, Asike MI, et al (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. <i>Gastroenterology</i> , 140(1): 124-31.
36181	Wolf AM, Busch B, Kuhlmann HW, et al (2005). Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. <i>Obes Surg</i> , 15(2): 228-37.
100952	Wolf PS, Park JO, Bao F, et al (2013). Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. <i>J Am Coll Surg</i> , 216(1): 41-9.
106302	Wu J, Xu H, He X, et al (2017). Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from 2007 to 2013. <i>Sci Rep</i> , 7: 41518.
106303	Xia Y, Wang X, Zhang S, et al (2019). Daily tea drinking is not associated with newly diagnosed non-alcoholic fatty liver disease in Chinese adults: the Tianjin chronic low-grade systemic inflammation and health cohort study. <i>Nutr J</i> , 18(1): 71.
106304	Xiong Y, Peng Q, Cao C, et al (2021). Effect of different exercise methods on non-alcoholic fatty liver disease: a meta-analysis and meta-regression. <i>Int J Environ Res Public Health</i> , 18(6): 3242.
67232	Yang Z, Wen J, Li Q, et al (2012). PPAR γ gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. <i>Mol Cell Endocrinol</i> , 348(1): 255-9.
106305	Yaryura-Tobias JA, Pinto A, Neziroglu F (2001). Anorexia nervosa, diabetes mellitus, brain atrophy, and fatty liver. <i>Int J Eat Disord</i> , 30(3): 350-3.
106306	Yasukawa K, Shimizu A, Yokoyama T, et al (2020). Preventive effect of high-dose digestive enzyme management on development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: a randomized controlled clinical trial. <i>J Am Coll Cardiol</i> , 231(6): 658-69.
106307	Yki-Jarvinen H, Luukkonen PK, Hodson L, et al (2021). Dietary carbohydrates and fats in nonalcoholic fatty liver disease. <i>Nat Rev Gastroenterol Hepatol</i> , 18(11): 770-86.
36238	Younossi ZM, Diehl AM, Ong JP (2002). Nonalcoholic fatty liver disease: an agenda for clinical research. <i>Hepatology</i> , 35(4): 746-52.
106308	Younossi ZM, Golabi P, de Avila L, et al (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>J Hepatol</i> , 71(4): 793-801.
67247	Younossi ZM, Stepanova M, Afendy M, et al (2011). Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. <i>Clin Gastroenterol Hepatol</i> , 9(6): 524-30.e1.
106309	Yu R, Shi Q, Liu L, et al (2018). Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis. <i>BMC Gastroenterol</i> , 18(1): 51.
106310	Zak A, Vecka M, Tvrzicka E, et al (2005). Composition of plasma fatty acids and non-cholesterol sterols in anorexia nervosa. <i>Physiol Res</i> , 54(4): 443-51.
67233	Zein CO, Unalp A, Colvin R, et al (2011). Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. <i>J Hepatol</i> , 54(4): 753-9.

67222	Zelber-Sagi S, Ratzu V, Oren R (2011). Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. <i>World J Gastroenterol</i> , 17(29): 3377-89.
106311	Zeng J, Yang RX, Sun C, et al (2020). Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. <i>World J Gastroenterol</i> , 26(15): 1792-804.
68477	Zhang H, He SM, Sun J, et al (2011). Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China. <i>Int J Med Sci</i> , 8(3): 254-62.
106312	Zhang Q, Ma X, Xing J, et al (2021). Serum uric acid Is a mediator of the association between obesity and incident nonalcoholic fatty liver disease: a prospective cohort study. <i>Front Endocrinol (Lausanne)</i> , 12: 657856.
106313	Zhang T, Zhang C, Zhang Y, et al (2015). Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. <i>Atherosclerosis</i> , 240(1): 144-8.
106314	Zhou BG, Yang HJ, Xu W, et al (2019). Association between <i>Helicobacter pylori</i> infection and nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies. <i>Helicobacter</i> , 24(3): e12576.
100953	Zhou DX, Bian XY, Cheng XY, et al (2016). Late gestational liver dysfunction and its impact on pregnancy outcomes. <i>Clin Exp Obstet Gynecol</i> , 43(3): 417-21.
106315	Zhou Y, Wei F, Fan Y (2016). High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Clin Biochem</i> , 49(7-8): 636-42.
67244	Zhou YJ, Li YY, Nie YQ, et al (2007). Prevalence of fatty liver disease and its risk factors in the population of South China. <i>World J Gastroenterol</i> , 13(47): 6419-24.
36793	Zimmet PZ, Alberti KG, Shaw JE (2005). Mainstreaming the metabolic syndrome: a definitive definition. <i>Med J Aust</i> , 183(4): 175-6.